Ibogaine Cost Projections Tool
This framework allows stakeholders to explore the economic dimensions of ibogaine-assisted care over time. Please note this page is for educational modeling only and does not provide financial or clinical guarantees.
Progection Tool
The Ibogaine progection tool serves as a bridge between clinical safety and economic viability. By integrating real-time health-tech monitoring with a structured economic framework, the tool allows stakeholders to see the financial impact through three primary lenses:
1.
Direct Cost Reduction
The tool focuses on optimizing the clinical delivery of therapy. Based on the modeling comparisons, the direct cost of Ibogaine treatment is approximately $124,000, compared to over $309,000 for the Standard of Care (SOC). The protection tool helps visualize this $185,000 per-patient saving by streamlining medical oversight and reducing the long-term healthcare utilization typically seen in traditional treatments.
2.
Validating the "Economic Dominance"
In economic modeling, a treatment is "dominant" when it is both more effective and less expensive. The tool tracks the QALY Delta (the 2.4-year gain in quality-adjusted life) alongside the financial data. The Visualization: It allows you to see the "Inverse ICER"—demonstrating that the investment in high-standard protection leads to a net economic gain of nearly $398,000 per person when considering the total ecosystem (direct and indirect costs).
3.
Risk Mitigation as a Financial Asset
By maintaining the "highest standards of safety," the protection tool effectively acts as an insurance mechanism. Lowering Indirect Costs: By preventing adverse events and ensuring a higher "Percentage Alive" (89.6%), the tool reduces the massive indirect costs associated with treatment failure and lost productivity. Pilot Study Readiness: It provides the data infrastructure needed for pilot studies, allowing you to prove the financial "mission statement" to investors or healthcare systems before a full-scale rollout.
Ibogaine Results
Ibogaine has shown promising results in resolving OWS within 36 to 48 hours of administration under safe, clinically-controlled conditions.
A systematic review of 743 published records related to the application of ibogaine for OWS concludes that ibogaine substantially eliminates OWS in patients who seek opioid abstinence. These studies found an immediate and prolonged reduction in opioid and cocaine craving.
In a study of participants who had used various opioids for at least 4 years, in which 69% of participants used opioids daily, 80% reported almost complete elimination of OWS within 34 hours. That percentage rises to 97% with a second supportive dose.
​
Educational Modeling Disclaimer
This tool is intended for conceptual modeling and educational purposes only. The cost projections, including clinic capacity, session expense ratios, and potential system-level savings, are illustrative examples and do not constitute financial, medical, or investment advice. Ibogaine-assisted care involves complex clinical and regulatory variables that significantly impact actual costs and outcomes. No guarantees of success or specific results are implied. Stakeholders are advised to consult with qualified legal, clinical, and financial professionals before embarking on projects or making investments based on these variables.